Determinants of Insulin Sensitivity by Age, Sex, Race/Ethnicity, BMI, and PCOS Diagnosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAli Chappell
About this trial
The study aims to investigate the relationship between fasting insulin and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) across various demographic factors, including age, sex, race/ethnicity, BMI, and polycystic ovary syndrome (PCOS) diagnosis. By analyzing these variables, the study seeks to identify potential variations in insulin levels, which could provide valuable insights into the impact of different factors on metabolic health and the development of insulin-related conditions.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Fasting insulin
Hemoglobin A1c (A1c)
Complete lipid panel
Triglycerides Laboratory testing must be completed through a healthcare provider, an independent laboratory, or by using an Insara Insulin Testing Kit Laboratory values must be obtained following a minimum 8-hour fast Participants must have complete laboratory data for all required measures
Disqualifiers
None
Trial population
The study aims to investigate the levels of Fasting Insulin and HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) among individuals with varying characteristics, including age, sex, race/ethnicity, BMI (Body Mass Index), and PCOS (Polycystic Ovary Syndrome) diagnosis. The study population consists of a diverse group of participants referred by healthcare providers and online platforms.
Trial design
Design model
Other
Time perspective
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Assessment of Fasting Insulin levels and HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) scores among different groups stratified by age, sex, race/ethnicity, BMI, and PCOS (Polycystic Ovary Syndrome) diagnosis.
The primary objective is to investigate the association between these measures and the specified demographic and clinical factors, providing insights into the variations and potential disparities in insulin resistance across different subgroups.
Time frame
3 yearsSecondary outcomes
1
Identify any significant interactions or relationships between the primary outcomes (Fasting Insulin and HOMA-IR) and the demographic and clinical factors, including age, sex, race/ethnicity, BMI, and PCOS diagnosis.
The secondary outcome measure will provide a comprehensive understanding of how various factors may influence insulin resistance and contribute to its heterogeneity in different populations.
Time frame
3 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Ali Chappell
Lead sponsor
Lilli Health
Sponsor institution
Source ClinicalTrials.gov